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confounding effects, only GHD patients (79/88; 89.7 % of 
the overall study population) were considered in the final 
analysis. The primary endpoint—adherence to treatment—
was calculated as the proportion of injections correctly 
administered during the observational period out of the 
expected total number of injections. The relevant informa-
tion, tracked by the easypod™, was collected at months 6 
(V1) and 12 (V2) after baseline (V0). At study termination, 
adherence data were partially available from 16 patients 
and fully available from 53 patients. As secondary end-
points, serum IGF-1 levels, fasting serum glucose and insu-
lin levels and key anthropometric characteristics (height, 
waist circumference and BMI) were also determined.
Results The easypod™ data showed that 56.7 % of the 
patients were considered to be fully (≥92 %) adherent to 
their treatment throughout the period V0–V2. Treatment 
improved stature, significantly increased IGF-1 and pro-
duced a non-significant increase in blood glucose and insu-
lin levels.
Conclusions The injection-recording system and other 
characteristics of easypod™ could enhance the ability of 
physicians to monitor adherence to r-hGH treatment.
Keywords Growth disorders (GD) · IGF-1 · Easypod™ · 
Adherence
Introduction
Growth hormone (GH) has been used as an elective treat-
ment for severely GH-deficient children and adolescents 
since the 1960s [1]. Due to the limited availability of 
human pituitary-derived hormone, GH use for other con-
ditions related to short stature could not be seriously con-
sidered until the mid-1980s, when recombinant human 
Abstract 
Purpose Poor adherence to recombinant human growth 
hormone (r-hGH) therapy is associated with reduced 
growth velocity in children with growth hormone defi-
ciency (GHD). This twelve-month observational study 
was to assess adherence in r-hGH patients treated with the 
easypod™, an electronic, fully automated injection device 
designed to track the time, date and dose administered.
Methods Ninety-seven prepubertal patients receiving 
r-hGH therapy were included in the study from ten Italian 
clinical sites and 88 completed the study. To avoid possible 
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GH (r-hGH) became available, thus opening up access to 
GH treatment to children and adolescents with causes of 
short stature other than GH deficiency (GHD) [2]. The 
indications for r-hGH in Italy are limited to the following 
conditions [3]: GHD, growth failure in girls with gonadal 
dysgenesis (Turner Syndrome), growth failure in prepuber-
tal children due to chronic renal failure (CRF) and failure 
of growth in short children born small for gestational age 
(SGA) [4]. The marketing authorisation (MA) of some 
marketed products has been extended to additional indica-
tions (e.g. Prader–Willi syndrome and short stature associ-
ated with altered function of the SHOX gene) [4].
The need for frequent injections over a long period of 
time has stimulated research into easier methods of admin-
istration, to improve patients’ adherence to their therapy. 
Non-adherence, as well as low adherence, is unavoidably 
associated with both individual and social treatment fail-
ures, such as less favourable clinical outcomes, lower qual-
ity of life and higher healthcare costs [5].
Several devices for r-hGH administration have been 
developed over time. So far, five broad categories of GH 
injection device are available, including syringes with nee-
dle, injection pens, self-injection pens, needle-free devices 
and electronic devices. As reported in a recent survey by 
patients, parents, physicians and nurses who had experience 
with administration of r-hGH, an optimal r-hGH device 
should fulfil the following characteristics: reliability; ease of 
use; lack of pain during injection; safety in use and storage 
and minimum number of steps before injection preparation. 
In addition, a good tracking system, allowing effective and 
objective monitoring of treatment adherence, was consid-
ered extremely important by the physicians [6–10].
Materials and methods
This was an observational, prospective study with the pri-
mary objective of monitoring adherence to r-hGH treatment 
for 1 year in prepubertal patients with growth disorders. The 
patients enrolled all received r-hGH therapy with the easy-
pod™ Clinical Kit, a system comprising an electronic, auto-
mated injection device (easypod™) with a docking station for 
recording r-hGH administration data to enable objective moni-
toring of actual drug usage. The secondary objectives were to 
monitor the effect of r-hGH treatment on serum IGF-1 concen-
trations, fasting serum glucose and insulin and on anthropo-
metric characteristics (height, waist circumference and BMI).
The first patient was enrolled on the 19th of March 
2010; the last study visit was performed on the 28th of 
January 2013. The study was approved by the ad hoc local 
ethics committees, and informed consent was obtained by 
patient’s parents or legal guardians. Eligibility for the study 
was based on the following inclusion criteria:
1. Prepubertal patients with short stature (under 14 years 
of age) with growth disorders receiving r-hGH therapy 
(according to the local SmPC), who were either naïve 
or unsatisfied with their current device and were can-
didates to continue r-hGH therapy with easypod™ 
according to clinical practice;
2. Receiving r-hGH prescribed according to the local 
SmPC;
3. Written informed consent obtained from the parent(s)/
legal guardian(s) at the beginning of the study.
Exclusion criteria included acquired GHD due to CNS 
tumour, infection, pituitary infiltration, history of cranial 
or spinal irradiation or cranial surgery; previous treatment 
with corticosteroids, except for topical or inhaled adminis-
tration for atopic disease and/or for hormonal substitution 
at a stable dosage for at least 3 months and concomitant 
significant diseases.
Approximately 100 patients were estimated as a suitable 
sample size for the assessment of their adherence to treat-
ment. Due to a slow recruitment rate, enrolment was stopped 
at the attainment of 97 participants. After one screening 
failure, a total of 96 patients were actually recruited. Eight 
patients did not complete the observational period for vari-
ous reasons, so 88 patients completed the study.
Due to the small number of patients with conditions 
other than GHD, and in order to avoid possible confound-
ing effects, only the 79 patients with GHD were included 
in the analysis data set. Patients could elect to discon-
tinue their participation at any time. The disposition of the 
patients is summarised in Table 1.
The study design is summarised in Fig. 1:
The study duration for each recruited patient was 1 year, 
unless they discontinued prematurely.
Each patient was enrolled in the study at baseline visit, 
after the assessment of eligibility criteria. Easypod™ 
devices were supplied by Merck Serono SpA, sponsor of 
the study. A support service, provided by the sponsor, was 
guaranteed to the enrolled patients in order to train them 
in correct device usage and replacement procedures, should 
malfunction of the device occur during the study.
Table 1  Patient disposition
Status Frequency Percentage
Screened 97 100
Screening failure 1 1
Enrolled 96 99
Early termination 8 8
Completed 88 92
Analysis data set (only GHD patients 79 82
1421J Endocrinol Invest (2016) 39:1419–1424 
1 3
Pursuant to the observational nature of the study, the 
r-hGH treatment was administered according to routine 
clinical practice, independent of the patient’s participation in 
the study. The outcome measurements for both the primary 
and the secondary endpoints were assessed at visits V0, V1 
and V2, respectively. The adherence to the treatment for each 
patient was estimated as the proportion of injections cor-
rectly administered during the observational period out of 
the expected total number of injections. The target rate for 
full adherence was defined as ≥92 % at the start of the study.
Adherence was calculated only for patients reporting at 
least 150 injections every 6 months (at least 300 injections 
throughout the overall 12-month observational period). The 
adherence rate was calculated as follows:
The statistical analysis was performed with SAS® soft-
ware, version 9.2 (SAS Institute, Cary, NC, USA). As this 
was an observational study, no distinction between inten-
tion to treat and per protocol data sets was made, no subsets 
were identified and only descriptive statistical analysis was 
performed. IGF-1 concentrations were measured by local 
laboratories using standard assays. IGF-1 SDS was calcu-
lated using the normative data for the method [11].
Results
Within an overall study population composed of 88 
enrolled subjects, 79 patients, all with GHD, were included 
in the final analysis. Of these, 52 (66 %) were male and 27 
Treatment adherence rate (%)
=
Number of days injections received during period
Number of days injections planned during period
× 100
(34 %) were female. Median age at enrolment was 10 years 
(interquartile range 9–12).
Adherence to treatment
Adherence data were available from 53/79 (67.09 %) par-
ticipants for the whole 12-month study period and from 
16/79 (20.25 %) patients for a 6-month follow-up (either 
from V0–V1 or from V1–V2). Only 16 patients reported 
≥150 injections over 6 months between V0–V1 and V1–
V2. Overall, 30/53 patients reported a total number of 
injections ≥300 across the whole observation period. Easy-
pod™ data showed that 17/30 (56.67 %) patients adminis-
tering at least 300 injections across the 1-year follow-up 
period completed the study with the preset target adher-
ence rate 92 %. With respect to the length of the follow-up 
period, administration data collected through the easypod™ 
were available from 28/53 (52.83 %) adherent patients. 
Relevant results are summarised in Tables 2 and 3.
Changes from baseline of height SDS were evalu-
ated, showing a significant increase in height across the 
12 months of follow-up (Table 4).
No correlation was found, using a linear regression 
model, between the change in height SDS among fully 
adherent patients (300 injections in the whole period) and 
the adherence rate (coefficient β = 0.01241, p = 0.123).
Serum glucose and insulin concentrations increased 
slightly, but not significantly, from baseline to V1 and V2, 
while IGF-1 significantly increased, as expected (Table 5).
Assessment of anthropometric characteristics revealed a 
statistically significant increase in height both at visit V1 
and V2 (Table 6).
A linear regression model showed no relationship between 
the changes observed in IGF-1 standard deviation score 
(IGF-1 SDS) and the adherence rate of patients with at least 
300 injections in the whole period (coefficient β = 0.01122, 
p = 0.8517). Detailed results are summarised in Fig. 2.
Discussion
In this study, we report the adherence rate measured by 
easypod in the 53 of 79 prepubertal patients with GHD (52 
Fig. 1  Study design and plan
Table 2  Adherence by number 
of injections
Adherence by number of injections (V0–V2)
Adherence rate Number of injections
<300 ≥300 Total
Frequency (%) <92 % 12 (22.64 %) 13 (24.53 %) 25 
(47.17 %)
Frequency (%) ≥92 % 11 (20.7 %) 17 (32.1 %) 28 (52.8 %)
Total (%) 23 (43.4 %) 30 (56.6 %) 53 (100 %)
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[66 %] boys, 27 [34 %] girls) for whom data were avail-
able, who had completed >300 injections over 12 months. 
Demographic characteristics of the patients included were 
consistent with the usual profile of easypod™ Clinical Kit 
users. The majority of patients showed good adherence to 
treatment, better than that reported in previous studies [12, 
13]. However, it must be stated that our study was prospec-
tive, and we used an objective method to measure adher-
ence. In addition, it must be pointed out that the patients 
(and their parents) were aware that adherence to treatment 
was being monitored and this fact may have influenced 
the outcome. We found no correlation between change in 
height SDS and the adherence rate. This may be due to the 
fact that the great majority of patients had a high adherence 
rate, and the number of patients was too small to find a cor-
relation with a parameter which varies very little.
As expected, we found a slight but non-significant 
increase in serum insulin and glucose concentrations. 
A number of studies have shown that such an increase 
Table 3  Adherence by follow-up period
Adherence Number of subjects (%)
Between V0 and V1 Not adherent 29 (45.3)
Adherent 35 (54.7)
Between V1 and V2 Not adherent 24 (41.4)
Adherent 34 (58.6)
Between V0 and V2 (whole 
study period)
Not adherent 25 (47.2)
Adherent 28 (52.8)
Table 4  Changes from baseline 
in height SDS
Changes from baseline n Mean Standard deviation Median Interquartile range p value
Height SDS V0 77 −2.2 0.8 −2.2 −2.67 to −1.79
Height SDS V2 76 −1.7 0.7 −1.7 −2.33 to −1.27
Height SDS V2–V0 75 0.5 0.3 0.5 0.25–0.64 <0.0001
Table 5  Changes from baseline in IGF-1 blood glucose and insulin levels
Changes from baseline and between visits n Mean Standard deviation Median Interquartile range p value
IGF-1 V0 (ng/mL) 67 204 129 183 116–256.3
IGF-1 V1 (ng/mL) 52 278 136 275 185.5–356.75
IGF-1 V1–V0 50 89 131 77 19–154 <0.0001
IGF-1 V2 (ng/mL) 63 290 143 292 162–374
IGF-1 V2–V0 54 97 148 88 42 – 158 <0.0001
Blood glucose V0 (mg/dL) 40 82 9 81 77–87
Blood glucose V1 (mg/dL) 56 86 9 87 81–92
Blood glucose V1–V0 39 2 9 1 −4 to 8 0.2262
Blood glucose V2 (mg/dL) 63 89 42 87 80–91
Blood glucose V2–V0 38 3 11 2 −5 to 9 0.2043
Insulin V0 (μU/mol) 37 6 5 5 3–8.25
Insulin V1 (μU/mol) 45 7 4 7 3.7–9.5
Insulin V1–V0 29 1 4 1 −0.9 to 4 0.1459
Insulin V2 (μU/mol) 51 8 6 7 4.99–10
Insulin V2–V0 28 1 4 1 −0.76 to 3.8 0.1628
Table 6  Changes from baseline in height parameters
Changes from baseline and between visits n Mean Standard deviation Median Interquartile range p value
Height V0 (cm) 79 126 16 129 118.7–136.2
Height V1 (cm) 79 130 16 133 122.3–141
Height V1–V0 79 4 2 4 3.3–5.5 <0.0001
Height V2 (cm) 79 134 15 137 126.7–144.6
Height V2–V0 79 8 2 8 6.7–9.5 <0.0001
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has no clinical significance [14, 15]. IGF-1 significantly 
increased but always remained within the normal range of 
concentrations.
The data collected by easypod™ Clinical Kit showed that 
56.67 % of patients were fully adherent (adherence 92 %) 
to treatment for the whole period of observation (V0–V2). 
Our results did not show a relationship between the changes 
observed in IGF-1 SDS and the adherence rate of patients 
with at least 300 injections in the whole period. Notably, 
IGF-1 concentrations significantly increased in the whole 
studied population both at V1 and at V2. Consequently, 
IGF-1 concentrations were increased to therapeutic levels in 
the overall population. Further studies are needed, either to 
specifically assess the minimum number of injections nec-
essary to achieve a therapeutic effect or to compare IGF-1 
SDS levels between adherent and non-adherent patients.
Adherence to treatment has been demonstrated to be 
critical for the achievement of both medical and economic 
expected outcomes of GH therapy [16–18]. However, 
Fisher et al. [18] have shown that non-adherence to GH 
therapy in paediatric patients is affected by several fac-
tors, among which the adoption of a needle-free injection 
device in place of a multi-dose injection pen may not play 
a crucial role, according to Verrips et al. [19]. Nevertheless, 
Cutfield et al. [20] have pointed out how subjective (parent-
reported) and objective (empty vial count) adherence rates 
may differ from one another, thus demonstrating unequivo-
cally the usefulness of a device, like the easypod™, that is 
able to collect objective data.
Conclusions
The results of the present study suggest that easypod™ may 
represent a helpful option that could assist physicians in 
effective monitoring of adherence to r-hGH treatment. The 
treatment resulted in significant changes in height SDS and 
IGF-1 concentrations. Further studies are needed to com-
pare growth and IGF-1 levels between adherent vs non-
adherent patients. Nevertheless, our study demonstrates 
that, even when therapeutic adherence is not strictly 
observed, but IGF-1 levels are maintained at therapeutic 
levels, with modern, easy to use, recombinant hormone for-
mulations, r-hGH supplementation is safe and efficacious.
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